Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer

Journal of Surgical Oncology

Volumn 81, Issue 3, 2002, Pages 138-143

  Epelbaum, Ron ^a,d   Rosenblatt, Edward ^a   Nasrallah, Suheil ^a   Faraggi, David ^b   Gaitini, Dianna ^a   Mizrahi, Solly ^c   Kuten, Abraham ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b UNIVERSITY OF HAIFA   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Chemoradiotherapy; Gemcitabine; Pancreatic cancer; Surgery

Indexed keywords

GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MALE; PANCREAS CANCER; PANCREAS RESECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, HIGH-ENERGY;

EID: 0036830375     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.10159     Document Type: Article

References (35)

1. Evans DB, Abbruzzese JL, Rich TA: Cancer of the pancreas. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds): "Cancer. Principles and Practice of Oncology." New York: Lippincott-Raven; 1997:1054-1087.
2. Moertel CG, Frytals S, Hahn RG, et al.: Therapy of locally unresectable pancreatic adenocarcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil) and high dose radiation + 5-fluorouracil. The Gastrointestinal Tumor Study Group. Cancer 1981;48:1705-1710.
3. Gastrointestinal Tumor study Group: Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988;80:751-755.
4. Kamthan AG, Morris JC, Dalton J, et al.: Combined modality therapy for stage II and III pancreatic carcinoma. J Clin Oncol 1997;15:2920-2927.
5. Bajetta E, Di Bartolomeo M, Chiara Stani S, et al.: Chemotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: Results of a feasibility study. Int J Radiat Oncol Biol Phys 1999;45:28528-28529.
6. Paulino AC, Latona C: Unresectable adenocarcinoma of the pancreas: Pattern of failure and treatment results. Cancer invest 2000;18:309-313.
7. Rothenberg ML, Moore MJ, Cripps MC, et al.: A phase II study of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996;7:347-353.
8. Burris HA, Moore MJ, Anderson J, et al.: Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15:2403-2413.
9. Lawrence TS, Eisbruch A, Shewach DS: Gemcitabine-mediated radiosensitization. Semin Oncol 1997;24(suppl 7):s7-24-s7-28.
10. Lawrence TS, Eisbruch A, McGinn CJ, et al.: Radiosensitization by gemcitabine. Oncology 1999;13(suppl 5):55-60.
11. Wolff RA, Evans DB, Gravel DM, et al.: Phase I trial of gemcitabine (GEM) combined with radiation (XRT) for the treatment of locally advanced pancreatic adenocarcinoma [abstract]. Proc Am Soc Clin Oncol 1998;17:283a.
12. Abad A, Arellano A, Brunet J, et al.: Gemcitabine plus radiotherapy in stage II-III pancreatic cancer: A phase I trial [abstract]. Ann Oncol 1998;9(suppl 4):53.
13. McGinn CJ, Smith DC, Szarka CE, et al.: A phase I study of gemcitabine (GEM) in combination with radiation therapy (RT) in patients with localized, unresectable pancreatic cancer [abstract]. Proc Am Soc Clin Oncol 1998;17:264a.
14. McGinn CJ, Shureiqi I, Eckhauser FE, et al.: Surgical resection following concurrent gemcitabine/radiation therapy in patients with previously unresectable pancreatic cancer [abstract]. Radiother Oncol 2000;56(suppl 1):s57.
15. Maurer U, Stegmeier P, Bolte R, et al.: Gemcitabine (G) in combination with radiation therapy (RT) in stage III-IV pancreatic cancer: First results of a current phase I study [abstract]. Eur J Cancer 1999;35(suppl 4):s148.
16. International Union Against Cancer (UICC): TNM classification of malignant tumors. In: Sobin LH, Wittekind C, (eds): New-York: Wiley-Liss; 1997. p 87-90.
17. National Cancer Institute: Guidelines for Reporting of Adverse Drug reactions. Bethesda, ND: Division of Cancer treatment, national Cancer Institute; 1988.
18. Miller AB, Hoogstraten B, Straquet M: Reporting results of cancer treatment. Cancer 1981;147:207-214.
19. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
20. Casper ES, Green MR, Kelsen DP, et al.: Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994;12:29-34.
21. Goor C, Scalliet P, Van Meerbeak J, et al.: A phase II study combining gemcitabine with radiotherapy in stage III NSCLC [abstract]. Ann Oncol 1996;7(suppl. 5):101.
22. Eisbruch A, Shewach DS, Urba S, et al.: Phase I trial of radiation (RT) concurrent with low-dose gemcitabine (GEM) for head and neck cancer: High mucosal and pharyngeal toxicity [abstract]. Proc Am Soc Clin Oncol 1997;6:386a.
23. Eisbruch A, Shewach DS, Bradford S, et al.: Radiation (RT) concurrent with low dose gemcitabine (GEM) for head and neck cancer: Interim results of phase I study [abstract]. Proc Am Soc Clin Oncol 1998;17:405a.
24. McGinn CJ: Concurrent gemzar and radiation therapy in pancreatic cancer. In "Treatment of Solid Tumors: A Clinical Update of Gemcitabine and MTA." Indianapolis: Lilly Global Medical Conference, 1999:56-57.
25. McGinn CJ, Shureiqi I, Robertson JM, et al.: A phase I trial of dose escalation with full dose gemcitabine (GEM) in patients (pts) with pancreatic cancer [abstract]. Proc Am Soc Clin Oncol 1999;18:274a.
26. Blackstock AW, Bernard SA, Richards F, et al.: Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 1999;17:2208-2212.
27. Welsh JS, Torre TG, DeWeese TL, O'Reilly S: Radiation myositis. Ann Oncol 1999;10:1105-1108.
28. Fisher BJ, Perera FE, Kocha W. et al.: Analysis of the clinical benefit of 5-fluorouracil and radiation treatment in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 1999;45:291-295.
29. Jessup JM, Steele G, Mayer RJ, et al.: Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg 1993;128:559-564.
30. Todd KE, Gloor B, Lane JS, et al.: Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin, leucovorin and dipyridamole. J Gastrointest Surg 1998;2:159-166.
31. Wagener DJ, Van Hoesel QG, Yap SH, et al.: Phase II trial of 5-fluorouracil, adriamycin and cisplatin (FAP) followed by radiation and 5-fluorouracil in locally advanced pancreatic cancer. Cancer Chemother Pharmacol 1989;25:131-134.
32. Kornek GV, Schratter-Sehn A, Marczell A, et al.: Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin. Br J Cancer 2000;82:98-103.
33. Kroep JR, Pinedo HM, Van Groeningen CJ, Peters GJ: Experimental drugs and drug combinations in pancreatic cancer. Ann Oncol 1999;10(suppl 4):s234-s238.
34. Brunner TB, Grabenbauer GG, Kastl S, et al.: Pancreatic carcinoma: Simultaneous radiochemotherapy with gemcitabine and cisplatin. A pilot study [abstract]. Eur J cancer 1999;35(suppl 4):s152.
35. Safar AM, Sanz Altmira P, Recht A, et al.: Phase I trial of gemcitabine, cisplatin (CDDP) and external beam radiation therapy (EBRT) for pancreatic cancer [abstract]. Proc Am Soc Clin Oncol 1999;18:227a.